Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.
Henry RR, Mudaliar S, Ciaraldi TP, Armstrong DA, Burke P, Pettus J, Garhyan P, Choi SL, Jacober SJ, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen N, Sinha VP, Linnebjerg H.
Henry RR, et al. Among authors: jacober sj.
Diabetes Care. 2014 Sep;37(9):2609-15. doi: 10.2337/dc14-0210. Epub 2014 Jun 19.
Diabetes Care. 2014.
PMID: 24947791
Clinical Trial.